ABSTRACT
Billions of doses of COVID-19 vaccines have been administered around the world, dramatically reducing SARS-CoV-2 incidence in some settings. Many studies suggest vaccines provide a high degree of protection against infection and disease, but precise estimates vary and studies differ in design, outcomes measured, dosing regime, location, and circulating virus strains. Here we conduct a systematic review of COVID-19 vaccines as of August 2021. We included efficacy data from Phase 3 clinical trials for 13 vaccines within the WHO Emergency Use Listing evaluation process and real-world effectiveness for 5 vaccines with observational studies meeting inclusion criteria. Vaccine metrics collected include effects against asymptomatic infection, any infection, symptomatic COVID-19, and severe outcomes including hospitalization and death, for both partial and complete vaccination, and against SARS-CoV-2 variants of concern. In addition, we review the epidemiological principles behind the design and interpretation of vaccine effects and explain important sources of heterogeneity between studies.
Competing Interest Statement
Study authors have received grant funding from the Bill & Melinda Gates Foundation (MMH, MDK, ALH, AAN), US National Institutes of Health (ALH), the US Centers for Disease Control and Prevention (SAT), and the US Department of Health and Human Services (ALH, SAT) for work unrelated to this project. CBJ and JGR received funding from the Novel Coronavirus Research Compendium at Johns Hopkins to conduct reviews of COVID-19 vaccine papers for other purposes. MMH and MDK have previously received support from a grant from Pfizer Inc to Johns Hopkins University for a non-COVID-19 vaccine. BW provided unpaid technical support to Bharat Biotech related to the clinical development of the BBV152 vaccine candidate. DRF previously served on an independent data monitoring committee for GlaxoSmithKline for a non-COVID-19 vaccine candidate. SAT served as an expert consultant for Milliman, Inc on future COVID-19 trajectories. All other authors declare no competing interests.
Funding Statement
The authors thank M Kate Grabowski and the Johns Hopkins University Novel Coronavirus Research Compendium for bringing the study authors together to work on this paper. MHH, AB, PS, KW, and MDK received funding to collect the data used in work through a contract from the WHO to the International Vaccine Access Center at Johns Hopkins University. ALH and AAN received support from the US National Institutes of Health (NIH DP5OD019851). All other authors received no specific funding support for this work. The study sponsors had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication. The views represented in this article do not necessarily reflect the views of the WHO or the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB was required for this review paper
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All VE metrics reported in the review are provided in the data supplement (Supplementary Table 1)